Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 1/20 | 0.36 |
| ▸ | ACHE | P22303 | 2/20 | 0.36 |
| ▸ | TP53 | P04637 | 1/20 | 0.36 |
| ▸ | TNKS | O95271 | 1/20 | 0.35 |
| ▸ | PARP1 | P09874 | 1/20 | 0.35 |
| ▸ | TNKS2 | Q9H2K2 | 1/20 | 0.35 |
| ▸ | BRD4 | O60885 | 1/20 | 0.35 |
| ▸ | CHRM2 | P08172 | 2/20 | 0.34 |
| ▸ | CHRM3 | P20309 | 2/20 | 0.34 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.34 |
| ▸ | CLPP | Q16740 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6045518 | 0.86 | CHRM2 (0.47) | CHRM2CHRM3ALDH1A1 | |
| SCHEMBL6045727 | 0.86 | TSHR (0.46) | ALDH1A1 | |
| SCHEMBL6045585 | 0.86 | OPRL1 (0.41) | ACHEALDH1A1 | |
| SCHEMBL6045421 | 0.85 | CYP2D6 (0.44) | ACHECHRM2CHRM3ALDH1A1 | |
| SCHEMBL6045483 | 0.84 | KDM4E (0.47) | ACHETP53ALDH1A1 | |
| Oxalic Acid SCHEMBL6045529 | 0.83 | CYP2D6 (0.42) | ACHECHRM2CHRM3ALDH1A1 | |
| Oxalic Acid SCHEMBL6045600 | 0.83 | KDM4E (0.50) | LMNATP53ALDH1A1 | |
| SCHEMBL6045478 | 0.83 | CHRM2 (0.34) | CHRM2CHRM3ALDH1A1 | |
| SCHEMBL6045541 | 0.82 | OPRM1 (0.42) | ALDH1A1 | |
| SCHEMBL6045636 | 0.82 | DRD4 (0.44) | LMNACHRM2CHRM3ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20060252797-A1 | Receptor regulator | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2006-11-09 | — | — | US | disclosed |
| EP-1559428-A1 | RECEPTOR REGULATOR | Takeda Pharmaceutical Company Limited (JP) | 2005-08-03 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060252797-A1 | Receptor regulator | NMUR1, NMUR2, NMBR | LMNA 1044/4885ACHE 3383/4885TP53 4876/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.